Cargando…

Case Report: Immune and Genomic Characteristics Associated With Hyperprogression in a Patient With Metastatic Deficient Mismatch Repair Gastrointestinal Cancer Treated With Anti-PD-1 Antibody

Microsatellite instability-high/deficient mismatch repair (MSI-H/dMMR) status of tumors is a distinct predictive biomarker of immune checkpoint inhibitors (ICIs) for colorectal and non-colorectal cancer populations. The overall response rate (ORR) varies from approximately 40% to 60%, indicating tha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Wenyue, Zhou, Yuwen, Yi, Cheng, Shu, Xinyao, Wei, Guixia, Chen, Xiaorong, Shen, Xudong, Qiu, Meng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8511698/ https://www.ncbi.nlm.nih.gov/pubmed/34659249 http://dx.doi.org/10.3389/fimmu.2021.749204

Ejemplares similares

Hyperprogression of a mismatch repair-deficient colon cancer in a humanized mouse model following administration of immune checkpoint inhibitor pembrolizumab
por: Sahin, Ilyas, et al.
Publicado: (2021)

Cervical Carcinosarcoma: Current Understanding on Pathogenesis, Diagnosis, Management and Future Perspectives
por: Shu, Xinyao, et al.
Publicado: (2021)

Intra-Abdominal Desmoplastic Small Round Cell Tumor: Current Treatment Options and Perspectives
por: Wei, Guixia, et al.
Publicado: (2021)

Advances in the Study of Hyperprogression of Different Tumors Treated with PD-1/PD-L1 Antibody and the Mechanisms of Its Occurrence
por: Zheng, Jianpei, et al.
Publicado: (2023)

Mismatch repair deficiency in metastatic prostate cancer: Response to PD-1 blockade and standard therapies
por: Graham, Laura S., et al.
Publicado: (2020)

Clinical Characteristics and Outcome Between Gallbladder Squamous Cell Carcinoma and Adenocarcinoma: A Propensity Matched Analysis Based on the Surveillance, Epidemiology, and End Results Database
por: Chen, Xiaorong, et al.
Publicado: (2022)

Universal Screening of Gastrointestinal Malignancies for Mismatch Repair Deficiency at Stanford
por: Abrha, Aser, et al.
Publicado: (2020)

The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy
por: Wang, Xueping, et al.
Publicado: (2020)

Controversies and management of deficient mismatch repair gastrointestinal cancers in the neoadjuvant setting
por: Boutin, Mélina, et al.
Publicado: (2023)

Hyperprogressive Disease in Anorectal Melanoma Treated by PD-1 Inhibitors
por: Faure, Marjorie, et al.
Publicado: (2018)

PD-1(+) regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
por: Kamada, Takahiro, et al.
Publicado: (2019)

Genomic alterations associated with pseudoprogression and hyperprogressive disease during anti-PD1 treatment for advanced non-small-cell lung cancer
por: Zhou, Rui, et al.
Publicado: (2023)

Clinical responses to PD-1 inhibition and their molecular characterization in six patients with mismatch repair-deficient metastatic cancer of the digestive system
por: Hirsch, Daniela, et al.
Publicado: (2020)

Hyperprogressive Disease Caused by PD-1 Inhibitors for the Treatment of Pan-Cancer
por: Chen, Shiyun, et al.
Publicado: (2021)

Hyperprogression of cutaneous T cell lymphoma after anti–PD-1 treatment
por: Gao, Yumei, et al.
Publicado: (2023)

Prognostic and Predictive Values of Mismatch Repair Deficiency in Non-Metastatic Colorectal Cancer
por: Jin, Zhaohui, et al.
Publicado: (2021)

Organoids and metastatic orthotopic mouse model for mismatch repair-deficient colorectal cancer
por: Song, Yurong, et al.
Publicado: (2023)

Mixed lineage kinase 3 gene mutations in mismatch repair deficient gastrointestinal tumours
por: Velho, Sérgia, et al.
Publicado: (2010)

Hyperprogression under Immunotherapy
por: Frelaut, Maxime, et al.
Publicado: (2019)

Hyperprogression after immunotherapy
por: Abbas, Waseem, et al.
Publicado: (2019)

Hyperprogressive disease during PD-1 blockade in patients with advanced pancreatic cancer
por: Chen, Shiyun, et al.
Publicado: (2023)

Association of Peripheral Blood Biomarkers With Response to Anti-PD-1 Immunotherapy for Patients With Deficient Mismatch Repair Metastatic Colorectal Cancer: A Multicenter Cohort Study
por: Cheng, Yi-Kan, et al.
Publicado: (2022)

Hyperprogression in Pediatric Melanoma Metastatic to the Breast Treated with a Checkpoint Inhibitor
por: Bernal Vaca, Laura, et al.
Publicado: (2019)

Mismatch repair deficiency in ovarian cancer
por: Fuh, Katherine
Publicado: (2022)

Clinical Characterization of Mismatch Repair Gene-Deficient Metastatic Castration-Resistant Prostate Cancer
por: Ye, Senlin, et al.
Publicado: (2020)

Survival of patients with deficient mismatch repair metastatic colorectal cancer in the pre-immunotherapy era
por: Wensink, G. Emerens, et al.
Publicado: (2020)

Immunogenomic Landscape Contributes to Hyperprogressive Disease after Anti-PD-1 Immunotherapy for Cancer
por: Xiong, Donghai, et al.
Publicado: (2018)

Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy
por: Zhao, Pengfei, et al.
Publicado: (2019)

Hyperprogression after Immunotherapy: Nivolumab. Analysis of Imaging Findings Associated with Hyperprogression and Tumor Growth Kinetics
por: Singla, Rishu, et al.
Publicado: (2021)

Role of Deficient Mismatch Repair in the Personalized Management of Colorectal Cancer
por: Zhang, Cong-Min, et al.
Publicado: (2016)

Immune Checkpoint Inhibition in Metastatic Colorectal Cancer Harboring Microsatellite Instability or Mismatch Repair Deficiency
por: Cohen, Romain, et al.
Publicado: (2021)

Impact of mismatch-repair deficiency on the colorectal cancer immune microenvironment
por: Zhang, Yingyi, et al.
Publicado: (2017)

Redefine Hyperprogressive Disease During Treatment With Immune-Checkpoint Inhibitors in Patients With Gastrointestinal Cancer
por: Wang, Zhenghang, et al.
Publicado: (2021)

Biallelic Mismatch Repair Deficiency in an Adolescent Female
por: Hildreth, Amber, et al.
Publicado: (2018)

Assessment of mismatch repair deficiency in ovarian cancer
por: Crosbie, Emma J, et al.
Publicado: (2021)

Genetic Characteristics of Mismatch Repair-deficient Glioblastoma
por: KAWAGUCHI, Kei, et al.
Publicado: (2021)

Unexplained mismatch repair deficiency: Case closed
por: Eikenboom, Ellis L., et al.
Publicado: (2022)

Efficacy and safety of preoperative immunotherapy in patients with mismatch repair-deficient or microsatellite instability-high gastrointestinal malignancies
por: Li, Ying-Jie, et al.
Publicado: (2023)

Association Between Survival and Metastatic Site in Mismatch Repair–Deficient Metastatic Colorectal Cancer Treated With First-line Pembrolizumab
por: Saberzadeh-Ardestani, Bahar, et al.
Publicado: (2023)

Hyperprogressive Disease and Early Hypereosinophilia After Anti-PD-1 Treatment: A Case Report
por: Occhipinti, Mario, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_99mqrf3tvihprtf0k8aopls64p